Macrophage Pharma is an immuno-oncology company focussed on the discovery and development of novel therapies designed to enhance anti-tumour immune responses.

Macrophage Pharma’s technology platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner to activate the body’s natural immune system to fight cancer.

Macrophage Pharma’s novel Esterase Sensitive Motif (ESM™) technology has delivered agents which are being developed to induce targeted and durable anti-tumour immune responses and provide next-generation immunotherapy with broad utility in oncology.

Macrophage Pharma’s approach is to create a more hostile environment for tumour growth by:

  • Reprogramming tumour macrophages to stimulate the anti-tumour immune response
  • Reversing immunosuppression in the tumour microenvironment
  • Converting tolerogenic dendritic cells to effective antigen presenting cells

The company is exploiting a unique and proprietary knowledge base to unleash the full therapeutic potential of ESM technology in immuno-oncology.

Our Approach

OUR APPROACH

Macrophage Pharma’s primary goal is to develop a new generation of powerful small-molecule immuno-oncology drugs which inhibit the ability of tumour polarised macrophages to release immunosuppressive cytokines.

more details…

ESM Technology

ESM™ TECHNOLOGY

The foundation of Macrophage Pharma’s approach is its proprietary Esterase Sensitive Motif (ESM™) technology. The technology involves the use of specifically designed amino acid ester motifs that are selectively hydrolysed.

more details…

Research Projects

R&D PROJECTS

Macrophage Pharma’s lead programme is focused on the novel macrophage targeted p38 MAPK inhibitor, CHR-6155, supported by a strong package of non-clinical immuno-oncology and early safety pharmacology data.

more details…